Chronic traumatic encephalopathy
(CTE), a unique tauopathy, is
pathologically associated with the aggregation of hyperphosphorylated
tau protein into fibrillar aggregates. Inhibiting tau aggregation
and disaggregating tau protofibril might be promising strategies to
prevent or delay the development of CTE. Newly resolved tau fibril
structures from deceased CTE patients’ brains show that the
R3-R4 fragment of tau forms the core of the fibrils and the structures
are distinct from other tauopathies. An in vitro experiment finds
that epigallocatechin gallate (EGCG) can effectively inhibit human
full-length tau aggregation and disaggregate preformed fibrils. However,
its inhibitive and destructive effects on the CTE-related R3-R4 tau
and the underlying molecular mechanisms remain elusive. In this study,
we performed extensive all-atom molecular dynamics simulations on
the CTE-related R3-R4 tau dimer/protofibril with and without EGCG.
The results reveal that EGCG could reduce the β-sheet structure
content of the dimer, induce the dimer to form loosely packed conformations,
and impede the interchain interactions, thus inhibiting the further
aggregation of the two peptide chains. Besides, EGCG could reduce
the structural stability, decrease the β-sheet structure content,
reduce the structural compactness, and weaken local residue–residue
contacts of the protofibril, hence making the protofibril disaggregated.
We also identified the dominant binding sites and pivotal interactions.
EGCG preferentially binds with hydrophobic, aromatic, and positively/negatively
charged residues of the dimer, while it tends to bind with polar,
hydrophobic, aromatic, and positively charged residues of the protofibril.
Hydrophobic, hydrogen-bonding, π–π stacking, and
cation−π interactions synergistically drive the binding
of EGCG on both the dimer and the protofibril, but anion−π
interaction only exists in the interaction of EGCG with the dimer.
Our work unravels EGCG’s inhibitive and destructive effects
on the CTE-related R3-R4 tau dimer/protofibril and the underlying
molecular mechanisms, which provides useful implications for the design
of drugs to prevent or delay the progression of CTE.